| Efficacy and safety of trifluridine/tipiracil-containing combinations in colorectal cancer and other advanced solid tumors: a systematic review. | 2024 | The Oncologist |
| Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis. | 2024 | BMC Gastroenterology |
| Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis. | 2024 | Therapeutic Advances in Medical Oncology |
| Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis. | 2024 | Frontiers in Oncology |
| Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis. | 2024 | Diagnostic and Interventional Radiology |
| Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: a systematic review and external pseudodata-based analysis. | 2024 | Neuro-Oncology Advances |
| The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials. | 2024 | Frontiers in Pharmacology |
| Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis. | 2024 | Frontiers in Pharmacology |
| Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review. | 2024 | BMC Geriatrics |
| Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: a systematic review and meta-analysis in anorectal medicine. | 2024 | International Wound Journal |
| Efficacy of anti-VEGF drugs based combination therapies in recurrent glioblastoma: systematic review and meta-analysis. | 2024 | Current Reviews in Clinical and Experimental Pharmacology |
| A systematic review of nanomedicine in glioblastoma treatment: clinical efficacy, safety, and future directions. | 2023 | Brain Sciences |
| Efficacy and safety of bevacizumab for treating glioblastoma: a systematic review and meta-analysis of phase II and III randomized controlled trials. | 2023 | Cancer Investigation |
| Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis. | 2023 | Frontiers in Oncology |
| Atezolizumab in combination with bevacizumab for the management of patients with hepatocellular carcinoma in the first-line setting: systematic literature review and meta-analysis. | 2023 | Liver Cancer |
| Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: a meta-analysis. | 2023 | PLoS One |
| Proteasome inhibitors in the treatment of nonsmall cell lung cancer: a systematic review of clinical evidence. | 2023 | Health Science Reports |
| Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. | 2023 | Diseases |
| Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis. | 2023 | Therapeutice Advances in Chronic Disease |
| Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis. | 2023 | Frontiers in Oncology |
| Bevacizumab treatment for low-grade serous ovarian cancer: a systematic review. | 2023 | Current Oncology |
| Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Clinical and Experimental Hepatology |
| Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity. | 2023 | Journal of Neuro-Oncology |
| Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | EClinicalMedicine |
| Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials. | 2023 | European Journal of Medical Research |
| Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: a Bayesian network meta-analysis. | 2023 | Medicine |
| Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis. | 2023 | Frontiers in Pharmacology |
| Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis. | 2023 | BMC Cancer |
| Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: a systematic review. | 2023 | Frontiers in Pharmacology |
| Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis. | 2023 | Medicine |
| Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis. | 2023 | International Journal of Colorectal Disease |
| Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis. | 2023 | Frontiers in Pharmacology |
| Targeted therapies in patients with newly diagnosed glioblastoma-a systematic meta-analysis of randomized clinical trials. | 2023 | International Journal of Cancer |
| A systematic review and meta-analysis of trifluridine/tipiracil plus bevacizumab for the treatment of metastatic colorectal cancer: evidence from real-world series. | 2023 | Current Oncology |
| Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: a systematic review and network meta-analysis. | 2023 | PLoS One |
| Treatment options for recurrent platinum-resistant ovarian cancer: a systematic review and Bayesian network meta-analysis based on RCTs. | 2023 | Frontiers in Oncology |
| Impact of neoadjuvant chemotherapy on post-hepatectomy regeneration for patients with colorectal cancer liver metastasis - systematic review and meta-analysis. | 2023 | European Journal of Surgical Oncology |
| Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: a systematic literature review and network meta-analysis. | 2023 | Lung Cancer |
| Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: a Bayesian network meta-regression analysis. | 2023 | Frontiers in Oncology |
| First-line systemic therapies for advanced hepatocellular carcinoma: a systematic review and patient-level network meta-analysis. | 2023 | Liver Cancer |
| Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis. | 2023 | Therapeutic Advances in Medical Oncology |
| Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. | 2023 | Frontiers in Immunology |
| Immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: a meta-analysis. | 2023 | Current Oncology |
| Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials. | 2023 | Annals of Medicine |
| Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: a network meta-analysis. | 2022 | Frontiers in Oncology |
| Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: a systematic review of randomized controlled trials. | 2022 | Medicine |
| A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: a Bayesian network meta-analysis. | 2022 | Frontiers in Pharmacology |
| Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. | 2022 | Acta Oncologica |
| A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. | 2022 | Frontiers in Immunology |
| Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis. | 2022 | Therapeutic Advances in Medical Oncology |
| Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. | 2022 | International Journal of Gynecological Cancer |
| Efficacy and safety of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor combination therapy as first-line treatment for patients with advanced EGFR-mutated, non-small cell lung cancer: a systematic review and bayesian network meta-analysis. | 2022 | Cancers |
| Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. | 2022 | European Journal of Cancer |
| Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: a network meta-analysis of randomized sorafenib-controlled trials. | 2022 | Hepatology Communications |
| First- and second-line treatments for patients with advanced hepatocellular carcinoma in China: a systematic review. | 2022 | Current Oncology |
| Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. | 2022 | Discover Oncology |
| Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab. | 2022 | Frontiers in Pharmacology |
| A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: the state-of-the-art. | 2022 | Frontiers in Oncology |
| Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. | 2022 | BMJ Open |
| Safety assessment on serious adverse events of targeted therapeutic agents prescribed for RAS wild-type metastatic colorectal cancer: systematic review and network meta-analysis. | 2022 | International Journal of Environmental Research and Public Health |
| Overall survival benefits of first-line treatments for asian patients with advanced epidermal growth factor receptor-mutated NSCLC harboring exon 19 deletion: a systematic review and network meta-analysis. | 2022 | Cancers |
| Clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with liver metastases: a network meta-analysis of nine randomized controlled trials. | 2022 | Cancer Research and Treatment |
| The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects. | 2022 | International Journal of Molecular Sciences |
| Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis. | 2022 | Translational Cancer Research |
| Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. | 2022 | ESMO Open |
| Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis. | 2022 | JTO Clinical and Research Reports |
| FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. | 2022 | European Journal of Cancer |
| First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: a Bayesian network meta-analysis of randomized controlled trials. | 2022 | Cancer Medicine |
| Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis. | 2022 | Journal of the National Cancer Institute |
| What is long-term survival and which first-line immunotherapy brings long-term survival for advanced wild-type non-small cell lung cancer: a network meta-analysis based on integrated analysis. | 2022 | Frontiers in Immunology |
| Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. | 2022 | BMC Cancer |
| Combined immunotherapy with chemotherapy versus bevacizumab with chemotherapy in first-line treatment of driver-gene-negative non-squamous non-small cell lung cancer: an updated systematic review and network meta-analysis. | 2022 | Journal of Clinical Medicine |
| A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer. | 2022 | Scientific Reports |
| Protective ostomies in ovarian cancer surgery: a systematic review and meta-analysis. | 2022 | Journal of Gynecologic Oncology |
| Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. | 2022 | Cochrane Database of Systematic Reviews |
| Efficacy and safety of systemic treatments among colorectal cancer patients: a network meta-analysis of randomized controlled trials. | 2022 | Frontiers in Oncology |
| Pretreatment ADC histogram analysis as a prognostic imaging biomarker for patients with recurrent glioblastoma treated with bevacizumab: a systematic review and meta-analysis. | 2022 | American Journal of Neuralradiology |
| The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials. | 2022 | Journal of Clinical Pharmacy and Therapeutics |
| Tolerability on serious adverse events of first-line bevacizumab and cetuximab for RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. | 2022 | Healthcare |
| Efficacy and safety of immunotherapy for cervical cancer-a systematic review of clinical trials. | 2022 | Cancers |
| Treatment patterns for advanced non-small cell lung cancer in the US: a systematic review of observational studies. | 2022 | Cancer Treatment and Research Communications |
| Risk and incidence of infection with bevacizumab in non-small-cell lung cancer patients: a meta-analysis. | 2022 | Oncology Research and Treatment |
| Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: a meta-analysis. | 2022 | Thoracic Cancer |
| Efficacy and safety of bevacizumab biosimilars compared with reference biologics in advanced non-small cell lung cancer or metastatic colorectal cancer patients: a network meta-analysis. | 2022 | Frontiers in Pharmacology |
| The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects. | 2022 | International Journal of Molecular Sciences |
| Pneumothorax as a complication of bevacizumab-containing chemotherapy: a systematic review of case reports. | 2022 | Cureus |
| The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: a systematic review and meta-analysis. | 2021 | Medicine |
| Effectiveness and safety of adding bevacizumab to platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer: a meta-analysis. | 2021 | Frontiers in Medicine |
| Efficacy and safety of bevacizumab combined with EGFR-TKIs in advanced non-small cell lung cancer: a meta-analysis. | 2021 | Thoracic Cancer |
| The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials. | 2021 | Journal of Clinical Pharmacy and Therapeutics |
| Bevacizumab treatment of radiation-induced brain necrosis: a systematic review. | 2021 | Frontiers in Oncology |
| Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis. | 2021 | Medicine |
| The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis. | 2021 | Gynecologic Oncology |
| First-line systemic treatment strategies for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis of randomized clinical trials. | 2021 | Frontiers in Oncology |
| Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis. | 2021 | BMJ Open |
| Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis. | 2021 | JAMA Network Open |
| Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO. | 2021 | ESMO Open |
| A comparison of bevacizumab plus TAS-102 and TAS-102 monotherapy for metastatic colorectal cancer: a systematic review and meta-analysis. | 2021 | Frontiers in Oncology |
| Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: a systematic review. | 2021 | World Journal of Gastrointestinal Oncology |
| Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis. | 2021 | European Review for Medical and Pharmacological Sciences |
| Risk of thrombo-embolic events in ovarian cancer: does bevacizumab tilt the scale? A systematic review and meta-analysis. | 2021 | Cancers |
| The safety and effectiveness of bevacizumab in the treatment of nonsquamous non-small-cell lung cancer: a meta-analysis of randomized controlled trials. | 2021 | BioMed Research International |
| Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). | 2021 | Gastroenterology |
| Non-surgical management of advanced hepatocellular carcinoma: a systematic review by Cancer Care Ontario. | 2021 | Canadian Liver Journal |
| Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: a systematic review and meta-analysis. | 2021 | Medicine |
| Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: a meta-analysis. | 2021 | Cancer |
| Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. | 2021 | Journal of Thoracic Oncology |
| Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis of individual patients' data from 3 phase III studies. | 2021 | Cancer Treatment Reviews |
| Effectiveness and safety of adding bevacizumab to platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer: a meta-analysis. | 2021 | Frontiers in Medicine |
| Optimal maintenance strategy for first-line oxaliplatin-containing therapy with or without bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. | 2021 | Cancer Research and Treatment |
| Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review. | 2021 | Acta Neurochirurgica |
| The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2,402 patients. | 2021 | Oncologist |
| Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. | 2021 | Therapeutic Advances in Medical Oncology |
| Selection of first-line systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. | 2021 | World Journal of Gastroenterology |
| Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. | 2021 | Cochrane Database of Systematic Reviews |
| Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. | 2021 | Cochrane Database of Systematic Reviews |
| Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials. | 2021 | BMC Cancer |
| Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma. | 2021 | Neuro-Oncology Advances |
| Optimal therapies for recurrent glioblastoma: a Bayesian network meta-analysis. | 2021 | Frontiers in Oncology |
| Comparison of efficacy of systemic therapies in advanced hepatocellular carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials. | 2021 | Journal of Hepatocellular Carcinoma |
| Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. | 2021 | Cochrane Database of Systematic Reviews |
| Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. | 2021 | BMC Cancer |
| A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. | 2021 | Journal of Clinical Pharmacy and Therapeutics |
| Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review. | 2021 | Journal of the National Cancer Institute |
| Effectiveness of lomustine combined with bevacizumab in glioblastoma: a meta-analysis. | 2021 | Frontiers in Neurology |
| Network meta-analysis of first-line systemic treatment for patients with metastatic colorectal cancer. | 2021 | Cancer Control |
| The efficacy and safety of adding bevacizumab in neoadjuvant therapy for locally advanced rectal cancer patients: a systematic review and meta-analysis. | 2021 | Translational Oncology |
| Role of antiangiogenic agents combined with EGFR tyrosine kinase inhibitors in treatment-naive lung cancer: a meta-analysis. | 2021 | Clinical Lung Cancer |
| AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. | 2021 | Gastroenterology |
| Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. | 2020 | Cochrane Database of Systematic Reviews |
| Clinical and pathological characteristics of metastatic renal cell carcinoma patients needing a second-line therapy: a systematic review. | 2020 | Cancers |
| Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. | 2020 | JAMA Oncology |
| Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis. | 2020 | Translational Cancer Research |
| Targeted therapy for metastatic renal cell carcinoma. | 2020 | Cochrane Database of Systematic Reviews |
| Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis. | 2020 | JAMA Network Open |
| First-line treatment of metastatic renal cell carcinoma in the immuno-oncology era: systematic review and network meta-analysis. | 2020 | Clinical Genitourinary Cancer |
| Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. | 2020 | Aging |
| Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates. | 2020 | Neuro-oncology Practice |
| Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases. | 2020 | Annals of Palliative Medicine |
| Radiological recurrence patterns after bevacizumab treatment of recurrent high-grade glioma: a systematic review and meta-analysis. | 2020 | Korean Journal of Radiology |
| Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR-mutated non-small cell lung cancer: a meta-analysis. | 2020 | Frontiers in Oncology |
| Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma. | 2020 | Medicine |
| Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. | 2020 | OncoImmunology |
| Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis. | 2020 | International Journal of Molecular Sciences |
| Doublet vs single-agent maintenance therapy in the treatment of non-small-cell lung cancer: a meta-analysis. | 2020 | Drug Design, Development and Therapy |
| Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. | 2020 | Cochrane Database of Systematic Reviews |
| Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. | 2020 | ESMO Open |
| The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials. | 2020 | JAMA Oncology |
| A systematic review of systemic treatment options for advanced non-clear cell renal cell carcinoma. | 2020 | Kidney Cancer |
| Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. | 2020 | Medicine Open |
| Systemic bevacizumab (avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review. | 2020 | The Laryngoscope |
| First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. | 2019 | BMC Cancer |
| Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies. | 2019 | BMC Cancer |
| Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. | 2019 | Immunotherapy |
| Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients. | 2019 | Annals of Translational Medicine |
| Primary tumor resection in patients with incurable localized or metastatic colorectal cancer: a systematic review and meta-analysis. | 2019 | World Journal of Surgery |
| Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature. | 2019 | Journal of Neurosurgical Sciences |
| Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis. | 2019 | EBioMedicine |
| The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: a meta-analysis. | 2019 | Medicine Open |
| Comparative efficacy of preoperative, postoperative, and perioperative treatments for resectable colorectal liver metastases: a network meta-analysis. | 2019 | Frontiers in Pharmacology |
| Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. | 2019 | BMJ Open |
| AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: a meta-analysis using TRIBE, MAVERICC and FIRE3. | 2019 | International Journal of Cancer |
| Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: a systematic review and meta-analysis. | 2019 | Cancers |
| Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: a meta-analysis. | 2019 | Medicine Open |
| Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: a meta-analysis. | 2019 | Scientific Reports |
